“十一五”期间,国家通过“重大新药创制”等专项,投入近200亿元,使医药行业技术创新能力不断加强。但是,产业结构不合理、技术落后、产品同质化、内在质量低下等现象仍然存在,尤其在中小药企更为突出,造成的原因就是企业创新能力严重缺失,长期墨守于已有产品结构现状,不能适应医药卫生体制改革和医药市场新的变化。 During the 11th Five-Year Plan period, the state invested nearly 20 billion yuan in special projects such as “major new drug creation” and made the medical technology innovation capability continuously strengthened. However, such phenomena as unreasonable industrial structure, backward technology, homogeneity of products and low internal quality still exist, especially for small and medium-sized pharmaceutical enterprises, which is caused by the serious lack of innovation capability of enterprises and the long-term obsession with the current status of product structure , Can not adapt to medical and health system reform and new changes in the pharmaceutical market.